Reference
Medicines and Healthcare products Regulatory Agency. CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib): reports of interstitial lung disease and pneumonitis, including severe cases. Drug Safety Update 14: No. 11, 17 Jun 2021. Available from: URL: https://www.gov.uk/drug-safety-update/cdk4-slash-6-inhibitors-abemaciclibv-palbociclibv-ribociclibv-reports-of-interstitial-lung-disease-and-pneumonitis-including-severe-cases
Rights and permissions
About this article
Cite this article
Interstitial lung disease or pneumonitis with CDK 4/6 inhibitors. Reactions Weekly 1862, 3 (2021). https://doi.org/10.1007/s40278-021-98121-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-98121-x